Management of premenstrual syndrome

Journal of Family Planning and Reproductive Health Care

Volumn 35, Issue 3, 2009, Pages 187-194

  Panay, Nick ^a,b  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b QUEEN CHARLOTTE S AND CHELSEA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; ESTRADIOL; FLUOXETINE; PROGESTERONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; DRUG EFFICACY; GENETIC VARIABILITY; HUMAN; LUTEAL PHASE; PREMENSTRUAL SYNDROME; PREVALENCE; REVIEW; TREATMENT RESPONSE;

COGNITIVE THERAPY; COMPLEMENTARY THERAPIES; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; GREAT BRITAIN; HUMANS; PREMENSTRUAL SYNDROME; PREVALENCE;

EID: 67749111635     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118909788708147     Document Type: Review

References (62)

1. Royal College of Obstetricians and Gynaecologists (RCOG). Management of Premenstrual Syndrome (Green-top Guideline No. 48), Panay N (ed.). December 2007. http://www.rcog.org.uk/files/rcog-corp/uploaded-files/ GT48ManagementPremensturalSyndrome.pdf [Accessed 10 May 2009].
2. Magos AL, Studd JWW. The premenstrual syndrome. In: Studd J (ed.), Progress in Obstetrics and Gynaecology (Vol. 4). London, UK: Churchill Livingstone, 1984; 334-350.
3. Halbreich U, Backstrom T, Eriksson E, O'Brien S, Calil H, Ceskova E, et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol 2007; 23: 123-130. (Pubitemid 46570210)
4. Panay N, Studd JWW. The psychotherapeutic effects of estrogens. Gynecol Endocrinol 1998; 12: 353-365.
5. Huo L, Straub RE, Roca C, Schmidt PJ, Shi K, Vakkalanka R, et al. Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. Biol Psychiatry 2007; 62: 925-933. (Pubitemid 47496149)
6. Reid RL. Premenstrual syndrome. N Eng J Med 1991; 324: 1208-1210.
7. Sadler C, Inskip H, Smith H, Panay N. A study to investigate the relationship between lifestyle factors and premenstrual symptoms. Menopause Int 2004; 10(Suppl. 2): 15.
8. Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health 2006; 9: 41-49. (Pubitemid 43088573)
9. Prior JC, Vigna Y, Sciarretta D, Alojado N, Schulzer M. Conditioning exercise decreases premenstrual symptoms: a prospective, controlled 6-month trial. Fertil Steril 1987; 47: 402-408. (Pubitemid 17054208)
10. Girman A, Lee R, Kligler B. An integrative medicine approach to premenstrual syndrome. Am J Obstet Gynecol 2003; 188 (5 Suppl.): S56-S65. (Pubitemid 36589076)
11. Kleijnen J, Ter Riet G, Knipschild P. Vitamin B6 in the treatment of premenstrual syndrome - a review. Br J Obstet Gynaecol 1990; 97: 847-852. (Pubitemid 20283325)
12. Wyatt K, Dimmock P, Jones P, O'Brien P. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ 1999; 318: 1375-1381. (Pubitemid 29237827)
13. Facchinetti F, Borella P, Sances G, Fioroni L, Nappi RE, Genazzani AR. Oral magnesium successfully relieves premenstrual mood changes. Obstet Gynecol 1991; 78: 177-181.
14. Walker AF, De Souza MC, Vickers MF, Abeyasekera S, Collins ML, Trinca LA. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health 1998; 7: 1157-1165. (Pubitemid 128787259)
15. De Souza MC, Walker AF, Robinson PA, Bolland K. A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. J Womens Health Gend Based Med 2000; 9: 131-139. (Pubitemid 30168628)
16. Bertone-Johnson ER, Hankinson SE, Bendich A, Johnson SR, Willett WC, Manson JE. Calcium and vitamin D intake and risk of incident premenstrual syndrome. Arch Intern Med 2005; 165: 1246-1252. (Pubitemid 40989588)
17. Alvir JM, Thys-Jacobs S. Premenstrual and menstrual symptom clusters and response to calcium treatment. Psychopharmacol Bull 1991; 27: 145-148.
18. Thys-Jacobs S, Ceccarelli S, Bierman A, Weisman H, Cohen MA, Alvir J. Calcium supplementation in premenstrual syndrome: a randomized crossover trial. J Gen Intern Med 1989; 4: 183-189. (Pubitemid 19133703)
19. Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol 1998; 179: 444-452.
20. Burke BE, Olson RD, Cusack BJ. Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine. Biomed Pharm 2002; 56: 283-288. (Pubitemid 35245311)
21. Taher S, Cahill A, Eliahoo J, Calvin M, Rothon C, Panay N. Randomised placebo controlled pilot study comparing red clover (P-07) versus placebo for the treatment of premenstrual syndrome. Maturitas 2009; 63: S114-S115.
22. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo-controlled study. BMJ 2001; 322: 134-137. (Pubitemid 32116190)
23. Lauritzen C, Reuter HD, Repges R, et al. Treatment of premenstrual tension syndrome with Vitex agnus castus. Controlled, double-blind study versus pyridoxine. Phytomedicine 1997; 4: 183-189.
24. He Z, Chen R, Zhou Y, Geng L, Zhang Z, Chen S, et al. Treatment for premenstrual syndrome with Vitex agnus castus: a prospective, randomized, multi-center placebo controlled study in China. Maturitas 2009; 6 March [Epub ahead of print].
25. Stevinson C, Ernst E. A pilot study of Hypericum perforatum (St John's Wort) for the treatment of premenstrual syndrome. Br J Obstet Gynaecol 2000; 107: 870-876. (Pubitemid 30417343)
26. Huang KL, Tsai SJ. St. John's wort (Hypericum perforatum) as a treatment for premenstrual dysphoric disorder: case report. Int J Psychiatry Med 2003; 33: 295-297.
27. Khoo SK, Munro C, Battistutta D. Evening primrose oil and treatment of premenstrual syndrome. Med J Aust 1990; 153: 189-192. (Pubitemid 20241678)
28. Budieri D, Li-Wan Po A, Dornan JC. Is evening primrose oil of value in the treatment of premenstrual syndrome? Control Clin Trials 1996; 17: 60-68.
29. Cheung KL. Management of cyclical mastalgia in oriental women: pioneer experience of using gamolenic acid (Efamast) in Asia. Aust N Z J Surg 1999; 69: 492-494.
30. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992; 36: 257-266.
31. Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, et al.; PMS/PMDD Research Group. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001; 10: 561-569.
32. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72: 414-421. (Pubitemid 41676830)
33. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106: 492-501. (Pubitemid 41208780)
34. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95: 261-266. (Pubitemid 30045651)
35. Coffee AL, Kuehl TJ, Willis S, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 2006; 195: 1311-1319. (Pubitemid 44635376)
36. Magos AL, Brincat M, Studd J. Treatment of the premenstrual syndrome by subcutaneous oestradiol implants and cyclical oral norethisterone: placebo controlled study. BMJ 1986; 292: 1629-1633. (Pubitemid 16097868)
37. Watson NR, Studd JWW, Savvas M, Garnett T, Baber RJ. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989, 2(8665): 730-732. (Pubitemid 19243126)
38. Smith RNJ, Studd JWW, Zamblera D, Holland EF. A randomised comparison over 8 months of 100 mg and 200 mg twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 1995; 102: 475-484.
39. Panay N, Studd J. The management of PMDD through ovarian cycle suppression. In: S O'Brien S, Rapkin AJ, Schmidt PJ (eds), Premenstrual Syndromes: PMS and PMDD. London, UK: Informa Healthcare, 2007; 121-130.
40. Panay N, Studd J. Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum Reprod Update 1997; 3: 159-171. (Pubitemid 27389987)
41. Watts JF, Butt WR, Logan Edwards R. A clinical trial using danazol for the treatment of premenstrual tension. Br J Obstet Gynaecol 1987; 94: 30-34. (Pubitemid 17027526)
42. Hahn PM, Van Vugt DA, Reid RL. A randomised, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology 1995, 20: 193-209.
43. Wyatt KM, Dimmock PW, Ismail KM, Jones PW, O'Brien PM. The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: a meta analysis. Br J Obstet Gynaecol 2004; 111: 585-593.
44. Leather AT, Studd JWW, Watson NR, Holland EF. The prevention of bone loss in young women treated with GnRH analogues with add-back estrogen therapy. Obstet Gynecol 1993; 81: 104-107.
45. Di Carlo C, Palomba S, Tommaselli GA, Guida M, Di Spiezio Sardo A, Nappi C. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertil Steril 2001; 75: 380-384. (Pubitemid 32112118)
46. Sagsveen M, Farmer J, Prentice A, Breeze A. Gonadotrophin-releasing analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev 2003; (4): CD001297.
47. Wyatt K, Dimmock P, Jones P, Obhrai M, O'Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ 2001; 323: 1-8. (Pubitemid 32946762)
48. Magill PJ, Progesterone Study Group. Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. Br J Gen Pract 1995: 45: 589-593.
49. Cronje WH, Vashisht A, Studd JW. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod 2005; 19: 2152-2155. (Pubitemid 39236487)
50. Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R, Grover D, Streiner D. Fluoxetine in the treatment of premenstrual dysphoria. NEJM 1995;23:1529-1534.
51. Steiner M, Romano SJ, Babcock S, Dillon J, Shuler C, Berger C, et al. The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. Br J Obstet Gynecol 2001; 108: 462-468. (Pubitemid 32607309)
52. Dimmock PW, Wyatt KM, Jones PW, O'Brien PM. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 2000; 356(9236): 1131-1136.
53. Freeman E, Rickels K, Arredondo F, Kao LC, Pollack S, Sondheimer S. Full or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol 1999; 19: 3-8. (Pubitemid 29047324)
54. Yonkers K, Pearlstein T, Fayyad R, Gillespie J. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. J Affect Disord 2005; 85: 317-321. (Pubitemid 40386515)
55. Freeman EW, Jabara S, Sondheimer SJ, Auletto R. Citalopram in PMS patients with prior SSRI treatment failure: a preliminary study. J Womens Health Gend Based Med 2002; 11: 459-464. (Pubitemid 41246907)
56. Freeman EW, Sondheimer SJ, Sammel MD, Ferdousi T, Lin H. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for PMDD. J Clin Psychiatry 2005; 66: 769-773.
57. Hunter MS, Ussher JM, Browne SJ, Cariss M, Jelley R, Katz M. A randomized comparison of psychological (cognitive behaviour therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002; 23: 193-199. (Pubitemid 35252691)
58. Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet 2008; 371(9619): 1200-1210.
59. Panay N. Understanding the pain: managing severe PMS. Pract Midwife 2008; 11: 26-29.
60. Further reading/information 1 Ng C, Cloke B, Panay N. Management of severe premenstrual syndrome. In: Barter J, Hampton N (eds), The Year in Obstetrics & Gynaecology. Oxford, UK: Clinical Publishing Services, 2002; Part III, 181-196.
61. O'Brien S, Rapkin AJ, Schmidt PJ (eds). Premenstrual Syndromes: PMS and PMDD. London, UK: Informa Healthcare, 2007.
62. National Association for Premenstrual Syndrome (NAPS). Advice for sufferers and health professionals. Website: www.pms.org.uk.